Abstract
Objective: To identify genetic variants that play a role in the pathogenesis of multiple system atrophy (MSA), we undertook a genome-wide association study (GWAS). Methods: We performed a GWAS with >5 million genotyped and imputed single nucleotide polymorphisms (SNPs) in 918 patients with MSA of European ancestry and 3,864 controls. MSA cases were collected from North American and European centers, one third of which were neuropathologically confirmed. Results: We found no significant loci after stringent multiple testing correction. A number of regions emerged as potentially interesting for follow-up at p < 1 × 10-6, including SNPs in the genes FBXO47, ELOVL7, EDN1, and MAPT. Contrary to previous reports, we found no association of the genes SNCA and COQ2 with MSA. Conclusions: We present a GWAS in MSA. We have identified several potentially interesting gene loci, including the MAPT locus, whose significance will have to be evaluated in a larger sample set. Common genetic variation in SNCA and COQ2 does not seem to be associated with MSA. In the future, additional samples of well-characterized patients with MSA will need to be collected to perform a larger MSA GWAS, but this initial study forms the basis for these next steps.
Original language | English (US) |
---|---|
Pages (from-to) | 1591-1598 |
Number of pages | 8 |
Journal | Neurology |
Volume | 87 |
Issue number | 15 |
DOIs | |
State | Published - Oct 11 2016 |
ASJC Scopus subject areas
- Clinical Neurology
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'A genome-wide association study in multiple system atrophy'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Neurology, Vol. 87, No. 15, 11.10.2016, p. 1591-1598.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - A genome-wide association study in multiple system atrophy
AU - On behalf of the European Multiple System Atrophy Study Group
AU - the UK Multiple System Atrophy Study Group
AU - Sailer, Anna
AU - Scholz, Sonja W.
AU - Nalls, Michael A.
AU - Schulte, Claudia
AU - Federoff, Monica
AU - Price, T. Ryan
AU - Lees, Andrew
AU - Ross, Owen A.
AU - Dickson, Dennis W.
AU - Mok, Kin
AU - Mencacci, Niccolo E.
AU - Schottlaender, Lucia
AU - Chelban, Viorica
AU - Ling, Helen
AU - O'Sullivan, Sean S.
AU - Wood, Nicholas W.
AU - Traynor, Bryan J.
AU - Ferrucci, Luigi
AU - Federoff, Howard J.
AU - Mhyre, Timothy R.
AU - Morris, Huw R.
AU - Deuschl, Günther
AU - Quinn, Niall
AU - Widner, Hakan
AU - Albanese, Alberto
AU - Infante, Jon
AU - Bhatia, Kailash P.
AU - Poewe, Werner
AU - Oertel, Wolfgang
AU - Höglinger, Günter U.
AU - Wüllner, Ullrich
AU - Goldwurm, Stefano
AU - Pellecchia, Maria Teresa
AU - Ferreira, Joaquim
AU - Tolosa, Eduardo
AU - Bloem, Bastiaan R.
AU - Rascol, Olivier
AU - Meissner, Wassilios G.
AU - Hardy, John A.
AU - Revesz, Tamas
AU - Holton, Janice L.
AU - Gasser, Thomas
AU - Wenning, Gregor K.
AU - Singleton, Andrew B.
AU - Houlden, Henry
N1 - Funding Information: A. Sailer was supported in part by the Intramural Research Program of the National Institutes of Health (National Institute of Neurological Disorders and Stroke, National Institute on Aging; project number: Z01 AG000949). She also received funding support from the Multiple System Atrophy Trust, the Medical Research Council UK, and Wellcome Trust. S. Scholz was supported in part by the Intramural Research Program of the National Institutes of Health (National Institute of Neurological Disorders and Stroke, National Institute on Aging; project number: Z01 AG000949). She also received a R25 career development grant by the National Institute of Neurological Disorders and Stroke (grant number: R25 NS065729) and a Rapid Response Innovation Award by the Michael J. Fox Foundation. M. Nalls was supported in part by the Intramural Research Program of the National Institutes of Health (National Institute on Aging; project number: Z01 AG000949). C. Schulte reports no disclosures relevant to the manuscript. M. Federoff was supported in part by the Intramural Research Program of the National Institutes of Health (National Institute on Aging; project number: Z01 AG000949). T. Price was supported in part by the Intramural Research Program of the National Institutes of Health (National Institute of Neurological Disorders and Stroke, National Institute on Aging; project number: Z01 AG000949). A. Lees received funding support from the Multiple System Atrophy Trust, the Medical Research Council UK, Wellcome Trust, and the Reta Lila Weston Institute for Neurological Studies. O. Ross, D. Dickson, K. Mok, N. Mencacci, L. Schottlaender, and V. Chelban report no disclosures relevant to the manuscript. H. Ling receives funding from a CBD Solutions Research Grant and is employed by Reta Lila Weston Institute for Neurological Studies. S. O'Sullivan reports no disclosures relevant to the manuscript. N. Wood received funding support from the Multiple System Atrophy Trust, the Medical Research Council UK, Wellcome Trust, and the Reta Lila Weston Institute for Neurological Studies. B. Traynor was supported in part by the Intramural Research Program of the National Institutes of Health (National Institute on Aging; project number: Z01 AG000949). L. Ferrucci was supported in part by the Intramural Research Program of the National Institutes of Health (National Institute of Neurological Disorders and Stroke, National Institute on Aging; project number: Z01 AG000949). H. Federoff reports no disclosures relevant to the manuscript. T. Mhyre reports no disclosures relevant to the manuscript. H. Morris reports grants from Parkinson's UK and Medical Research Council UK during the conduct of the study and grants from Welsh Assembly Government, personal fees from Teva, personal fees from Abbvie, personal fees from Teva, personal fees from UCB, personal fees from Boehringer-Ingelheim, personal fees from GSK, nonfinancial support from Teva, grants from Ipsen Fund, nonfinancial support from Medtronic, grants from MNDA, grants from PSP Association, grants from CBD Solutions, grants from Drake Foundation, and personal fees from Acorda, outside the submitted work; in addition, Dr. Morris has a patent related to C9ORF72. H. R. M. is a co-applicant on a patent application related to C9ORF72: Method for diagnosing a neurodegenerative disease (PCT/GB2012/052140) pending. G. Deuschl, N. Quinn, H. Widner, A. Albanese, J. Infante, K. Bhatia, and W. Poewe report no disclosures relevant to the manuscript. W. Oertel has served as a consultant for Mundipharma, Novartis, and UCB Pharma; on advisory boards for Boehringer Ingelheim, Merck, Sharp & Dohme, Medtronic, Mundipharma, Neuropore, Novartis, UCB Pharma, and Teva; and received honoraria for presenting lectures from Abbvie, Desitin, Boehringer Ingelheim, Mundipharma, Novartis, Orion Pharma, Schwarz Pharma Neuroscience/UCB, and Teva. He has received scientific grants from the German Ministry of Education and Health, the German Research Foundation, the Charitable Hertie Foundation, the Internaal ParkinsonFonds, the Michael J. Fox Foundation, and Novartis Pharma Germany, and holds shares in Merck, Medigene, and Roche. G. Höglinger has served on the advisory boards for Abbvie, Asceneuron, Bristol-Myers Squibb, Roche, Sellas, and UCB; has received honoraria for scientific presentations from Abbvie, Roche, and UCB; has received research support from CurePSP, the International Parkinson Fonds, the German Academic Exchange Service (DAAD), German Research Foundation (DFG) and the German Ministry of Education and Research (BMBF), and the Sellas Life Sciences Group; and has received institutional support from the German Center for Neurodegenerative Diseases (DZNE). U. Wüllner, S. Goldwurm, M. Pellecchia, J. Ferreira, E. Tolosa, B. Bloem, O. Rascol, and W. Meissner report no disclosures relevant to the manuscript. J. Hardy received funding support from the Multiple System Atrophy Trust, the Medical Research Council UK, and Wellcome Trust. T. Revesz received funding support from the Multiple System Atrophy Trust, the Medical Research Council UK,Wellcome Trust, and the Reta Lila Weston Institute for Neurological Studies. J. Holton received funding support from the Multiple System Atrophy Trust, the Medical Research Council UK, Wellcome Trust, and the Reta Lila Weston Institute for Neurological Studies. T. Gasser and G. Wenning report no disclosures relevant to the manuscript. A. Singleton was supported in part by the Intramural Research Program of the National Institutes of Health (National Institute on Aging; project number: Z01 AG000949). H. Houlden received funding support from the Multiple System Atrophy Trust, the Medical Research Council UK, the Michael J. Fox Foundation, Wellcome Trust, and the Reta Lila Weston Institute for Neurological Studies. Publisher Copyright: © 2016 American Academy of Neurology.
PY - 2016/10/11
Y1 - 2016/10/11
N2 - Objective: To identify genetic variants that play a role in the pathogenesis of multiple system atrophy (MSA), we undertook a genome-wide association study (GWAS). Methods: We performed a GWAS with >5 million genotyped and imputed single nucleotide polymorphisms (SNPs) in 918 patients with MSA of European ancestry and 3,864 controls. MSA cases were collected from North American and European centers, one third of which were neuropathologically confirmed. Results: We found no significant loci after stringent multiple testing correction. A number of regions emerged as potentially interesting for follow-up at p < 1 × 10-6, including SNPs in the genes FBXO47, ELOVL7, EDN1, and MAPT. Contrary to previous reports, we found no association of the genes SNCA and COQ2 with MSA. Conclusions: We present a GWAS in MSA. We have identified several potentially interesting gene loci, including the MAPT locus, whose significance will have to be evaluated in a larger sample set. Common genetic variation in SNCA and COQ2 does not seem to be associated with MSA. In the future, additional samples of well-characterized patients with MSA will need to be collected to perform a larger MSA GWAS, but this initial study forms the basis for these next steps.
AB - Objective: To identify genetic variants that play a role in the pathogenesis of multiple system atrophy (MSA), we undertook a genome-wide association study (GWAS). Methods: We performed a GWAS with >5 million genotyped and imputed single nucleotide polymorphisms (SNPs) in 918 patients with MSA of European ancestry and 3,864 controls. MSA cases were collected from North American and European centers, one third of which were neuropathologically confirmed. Results: We found no significant loci after stringent multiple testing correction. A number of regions emerged as potentially interesting for follow-up at p < 1 × 10-6, including SNPs in the genes FBXO47, ELOVL7, EDN1, and MAPT. Contrary to previous reports, we found no association of the genes SNCA and COQ2 with MSA. Conclusions: We present a GWAS in MSA. We have identified several potentially interesting gene loci, including the MAPT locus, whose significance will have to be evaluated in a larger sample set. Common genetic variation in SNCA and COQ2 does not seem to be associated with MSA. In the future, additional samples of well-characterized patients with MSA will need to be collected to perform a larger MSA GWAS, but this initial study forms the basis for these next steps.
UR - http://www.scopus.com/inward/record.url?scp=84992046812&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84992046812&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000003221
DO - 10.1212/WNL.0000000000003221
M3 - Article
C2 - 27629089
AN - SCOPUS:84992046812
SN - 0028-3878
VL - 87
SP - 1591
EP - 1598
JO - Neurology
JF - Neurology
IS - 15
ER -